Cited by 1,697Pain Mechanisms and TreatmentsPeripheral Neuropathies and DisordersAldose Reductase and Taurine

Diabetic neuropathy

Feldman, Eva L., Callaghan, Brian C., Pop-Busui, Rodica, Zochodne, Douglas W., Wright, Douglas E., Bennett, David L., Bril, Vera, Russell, James W. +1 more·2019·Nature Reviews Disease Primers

Abstract

The global epidemic of prediabetes and diabetes has led to a corresponding epidemic of complications of these disorders. The most prevalent complication is neuropathy, of which distal symmetric polyneuropathy (for the purpose of this Primer, referred to as diabetic neuropathy) is very common. Diabetic neuropathy is a loss of sensory function beginning distally in the lower extremities that is also characterized by pain and substantial morbidity. Over time, at least 50% of individuals with diabetes develop diabetic neuropathy. Glucose control effectively halts the progression of diabetic neuropathy in patients with type 1 diabetes mellitus, but the effects are more modest in those with type 2 diabetes mellitus. These findings have led to new efforts to understand the aetiology of diabetic neuropathy, along with new 2017 recommendations on approaches to prevent and treat this disorder that are specific for each type of diabetes. In parallel, new guidelines for the treatment of painful diabetic neuropathy using distinct classes of drugs, with an emphasis on avoiding opioid use, have been issued. Although our understanding of the complexities of diabetic neuropathy has substantially evolved over the past decade, the distinct mechanisms underlying neuropathy in type 1 and type 2 diabetes remains unknown. Future discoveries on disease pathogenesis will be crucial to successfully address all aspects of diabetic neuropathy, from prevention to treatment.

Integrity signals

Registry

Crossref · 10.1038/s41572-019-0092-1

Cites

225 of 225 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Diabetic neuropathy involves various syndromes, such as mono- and polyneuropathies, plexopathies, radiculopathies and autonomic neuropathy, among which distal symmetric polyneuropathy is very prevalent.

    “Diabetic neuropathy involves various syndromes, such as mono- and polyneuropathies, plexopathies, radiculopathies and autonomic neuropathy, among which distal symmetric polyneuropathy is very prevalent (108).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V.
Affiliations
  • University of Michigan (US)
  • University of Alberta (CA)
  • University of Kansas Medical Center (US)
  • University of Oxford (GB)
  • University Health Network (CA)
  • VA Maryland Health Care System (US)
  • M.V. Hospital for Diabetes and Diabetes Research Centre (IN)
Corresponding author
Feldman, Eva L.
Venue
Nature Reviews Disease Primers
Published
2019-06-13
Volume
5
Issue
1
Pages
41-41
ISSN
2056-676X (ISSN-L)
OpenAlex
W4211145818
Cited by
1,697
References
225
Citations by year
2026: 246 · 2025: 337 · 2024: 364 · 2023: 272 · 2022: 220 · 2021: 149 · 2020: 78 · 2019: 13 · 2016: 1 · 2014: 3 · 2013: 2
FWCI
13.51
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs (101RX001030)
  • Diabetes Action Research and Education Foundation
  • Wellcome Trust (102645, 102645/Z/13/Z, 202747/Z/16/Z, 202747/Z/16/)
  • Diabetes Canada
  • European Commission (HORIZON2020)
  • Novo Nordisk Fonden (NNF14OC0011633)
  • National Institutes of Health (R01D107956)
  • Clinical Science Research and Development
  • Geriatric Research Education and Clinical Center
  • Canadian Institutes of Health Research
  • National Institute of Diabetes and Digestive and Kidney Diseases (R24DK082841, R01DK115687, R01DK107007)
  • National Institute of Neurological Disorders and Stroke (K23NS079417)
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
Keywords
diabetic neuropathy, distal symmetric polyneuropathy, type 1 diabetes, type 2 diabetes, glycemic control, prediabetes, neuropathic pain, neuropathy prevention, neuropathy treatment, opioid avoidance, pathogenesis
MeSH terms
Serotonin and Noradrenaline Reuptake Inhibitors, Analgesics, Opioid, Diabetic Neuropathies, Humans, Hyperglycemia, Hyperlipidemias, Mass Screening, Quality of Life, Risk Factors, Prevalence, Pain Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review